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    ABSTRACT 
Introduction: Leprosy is a chronic, infectious disease caused by Mycobacterium 
leprae. It is classified into five groups based on clinical, histological, 
microbiological and immunological criteria (Ridley & Jopling Classification). 
However, a great variation has been observed in the interpretation of 
histopathological examination of skin biopsies and clinical presentation of the 
disease. Histopathological examination of skin provides confirmatory diagnosis in 
suspected cases and gives indication of progression and regression of disease 
under treatment. This study is intended to demonstrate the concordance between 
clinical and histopathological diagnosis in leprosy. 
Method: : All cases attending the Hansen OPD were examined clinically and Slit 
Skin Smear was taken and stained with Ziehl-Neelsen stain for Acid Fast Bacilli. 
Skin Biopsy specimen was obtained from clinically diagnosed cases of Leprosy 
and stained with Hematoxylin & Eosin and modified Fite Ferraco . The clinical 
diagnosis correlated with histopathology in all 50 cases. 
Result: The age of the patients was ranged from 7 to 65 years. The male to female 
ratio of patients was 4.5 to 1. The majority of cases were in the age group of 21-40 
years belonging to low socioeconomic status. Borderline tuberculoid was the most 
common presentation. Highest parity was observed in LL(92.9%). Clinco-
histopathological agreement was seen in 40 (80%) cases, 10 (20%) cases shows  
disagreement. 
Conclusion: The clinical and histopathological features along with bacteriological 
index are useful than any single parameter in arriving definitive diagnosis and 
classification of the leprosy. 
1INTRODUCTION
Leprosy,  also  known  as  Hansen’s  disease,  is  one  of  the  oldest
disease of mankind. Leprosy still remains an important public health
problem  in many parts of Asia, mainly in India.
       In our country despite declaring leprosy elimination at national
level in January 2006 it is still a disease of endemic in many states. The
total estimated global new cases detected in 2009 were 2, 27, 849 and
India account 1,33,717 (58.7%) cases.
Depending on the immune status of the host, Leprosy  presents in
various clinico-pathological forms. Leprosy can be diagnosed by various
methods including detailed clinical examination of the skin lesions and
peripheral nerves, demonstration of the Acid Fast Bacilli (AFB) in slit
skin smears by Ziehl-Nielsen staining, Histopathological section,
demonstration of bacilli by modified Fite Faraco procedure10, and Fine
Needle Aspiration Cytology (FNAC) of nerves.
Ridley and Jopling have suggested immunological basis of
leprosy and classified into five types as Tuberculoid Leprosy (TT),
Borderline tuberculoid Leprosy (BT), Mid-borderline Leprosy (BB),
2Borderline Lepromatous Leorosy (BL), and Lepromatous Leprosy (LL).
This Classification is accepted worldwide and is highly recommended.
      Though the clinical diagnosis is based on characteristic
hypopigmented patches with sensory loss, a great variations are seen in
interpretation of these Hypopigmented skin lesions both clinically and
histo-pathologically.
So along with provided detailed clinical information and
bacilloscopic examination, skin biopsy play an important role in the
diagnosis of leprosy. Histopathological Examination also helps us to
ascertain the immunological status of the individual by which we can
predict the response to the treatment.
This research is taken to study the correlations between the
clinical and histo-pathological diagnosis of leprosy patients, and to
evaluate the importance of skin biopsy for the diagnosis of leprosy.
3REVIEW OF LITERATURE
DEFINITION
Leprosy is a slowly progressive, chronic granulomatous,
infectious disease caused by Mycobacterium leprae, and affecting the
skin, peripheral nervous system and certain other tissues.
HISTORICAL ASPECTS OF LEPROSY
Leprosy is a very ancient disease. The earliest possible account of
a disease that many scholars believe is leprosy appears in an Egyptian
Papyrus document written around 1550 B.C. Around 600 B.C. Indian
writings describe a disease that resembles leprosy. It has also found
mention in vedic writings as Kusht around 1400 BC. 1
The disease was probably carried from India to Europe in the 4th
century BC by  returning soldiers and camp followers from the Greek
wars of conquest in Asia, led by Alexander the Great. However the
earliest description of the disease as elephantiasis was unmistakably
leprosy by Arateus, in Greece, about 150 AD. 2
Through ages, leprosy has been feared and misunderstood, and
has resulted in significant stigma and isolation of those who are
afflicted. It was thought to be a hereditary disease, a curse and a
4punishment from the Gods. During the Middle Ages, those with leprosy
were forced to wear special clothing and ring bells to warn others of
their coming. 3
Noble families founded Leprosoria, hospitals for leprosy patients
between 12th and  15th centuries. Leprosy patients were legally
considered dead during that period.4
Moller Christensen’s work revealed that 80% of the skeleton
excavated at Naestved, Denmark showed the pathognomonic bony
changes.5
Carl William Boeck (1808 – 75) and Daniel Cornelius Danielssen
(1818 – 94), from Norway, two renowned leprosy experts of the
nineteenth century, believed that leprosy was a congenital disease and
not an infectious one.6
Dr. Gerhard Henrik Armauer Hansen (1841-1912) Danielssen’s
son-in-law, was the first person to identify the germ that causes leprosy
under a microscope (1873). Hansen's discovery of Mycobacterium
leprae proved that leprosy was caused by a germ and was thus not
hereditary, from a curse, or from a sin.7
5In 1882 Paul Ehrlich described the property of acid fastness.8
Schaffer in 1898 made a study in spread of leprosy by aerosols.9In 1909
Paul Unna postulated clustering of the bacilli into “globi” and  showed
the cell free sub epidermal zone in histological sections.10
In 1921, U.S. Public Health Service established the Gillis W.
Long Hansen’s Disease Center in Carville, Louisiana, which came to be
known as “Carville.” It became a center of research and testing to find a
cure for leprosy and a live-in treatment center for leprosy patients.
EPIDEMIOLOGY
GEOGRAPHICAL DISTRIBUTION
Although the worldwide prevalence of leprosy is less than one per
1000, still it is a public health problem in 15 countries including India,
Brazil, Myanmar and Nepal.11
The prevalence rate of leprosy in 2012 was 181 941 (0.34),
compared to 189 018 (0.33) at the end of the first quarter of 2013. The
overall incidence of new cases in 2012 was 232857, relatively greater
figures compared to earlier years. The South-East Asia Region
accounted for 71% of new cases detected worldwide, with 16% from
6Americas, 9% from the Africa Region and 2% each from the Eastern
Mediterranean and Western Pacific Regions.12
India contributes 58% to the world leprosy burden. In 2012-13,
India recorded 83,000 leprosy cases with a prevalence of 0.68 per
10,000 population. 33 states had attained the elimination level of less
than one case per 10,000 population. Two States, Bihar and
Chattisgharh are yet to achieve elimination (with a prevalence rate of
1.12 and 1.94, respectively). Of the total of 640 districts, 110 districts
still have prevalence rates between 1 and 2/10000, while in 530 districts,
elimination has been achieved.13
FACTORS IN TRANSMISSION OF LEPROSY
1.Agent factor
          2.Host factors
     3.Environmental factors
          4.Social factors
1. AGENT FACTORS
Leprosy is caused by Mycobacterium leprae. These are obligate
intra cellular parasite. M.leprae is a straight or slightly curved slender,
7capsulated, non-motile, non spore forming, acid- fast staining rods
which can be seen as clumps or bundles on microscopic examination.
They divides into two  in every 12 to 14 days. These are non cultivable
in artificial culture medium.14
M.leprae grows in cooler tissues like skin, peripheral nerves,
upper respiratory tract and testis, sparing warmer areas.15
The ultrastructure of M. leprae:
?  Capsule
?  Cell wall
?  Cell membrane
?  Cytoplasm
CAPSULE
Capsule is composed of phthiocerol demycocerosate and phenolic
glycolipid-1. This lipid capsule protects the bacteria from lysosomal
enzymes.PGL-1 is highly immunogenic, generating IgM class of
antibodies, demonstrable in 60 % of TT and 90 % of LL patients.16,17
8CELL WALL
This outer coat of bacteria protects from environment and gives
definite shape to the bacterial cell. It has an inner electron dense and an
outer electron transparent layer. It is composed of peptidoglycan-
arabinogalactone- mycolic acid complex,  alternating N-
acetylglucosamine and N-glycolylmuramate linked by peptide cross
bridges, which are linked to the galactan layer by arabinogalactan.
Mycolic acids are linked to the terminals of arabinan chains to form the
inner leaflet of a pseudolipid bilayer. The outer leaflet is composed of an
array of intercalating mycolic acids of trehalose  monomycolates and
mycoserosolic acids of phthiocerol dimycocerosates as well as phenolic
glycolipids. Cell wall is the last structure to disappear with
chemotherapy.18,19
CELL MEMBRANE
It contains proteins which controls the active and passive
transport of substances across  inside and outside of the cell. Two major
proteins are extracted, which are major membrane protein-I(MMP-I)
and major membrane protein-II(MMPII).20 MMP-I is a 35kDa protein.
The MMP-II is identical to mycobacterial bacterioferritin and it has
9large molecular mass of 380kDa.21 Cell membrane  also contains
phospholipids.22
CYTOPLASM
M.leprae cytoplasm contains three major proteins with molecular
weight of 28 kDa, 17 kDa and 28 kDa.20 It also contains storage
granules, DNA and RNA.
M.leprae can survive outside the human body for 2 to 9 days.It
secretes certain enzymes like superoxide dismutase and catalase, also
has DOPA oxidase activity.15, 16
2.  HOST FACTORS
Age:
Leprosy is more commonly seen in the age group 20 – 30 years,
but can occur at all ages from infants to very old age. In endemic areas,
it can occur in children, which indicates presence of active transmission
of the disease in the community.23
Sex:
Leprosy in adults is more prevalent among males than females,
genarally in the proportion of 2:1. In children there is no significant
difference between sexes.23,24
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Migration
Due to migration of population from rural to urban areas, leprosy
cases have increased in urban areas in recent years.15
Immunity
Occurrence of the disease  depends on immunological status of an
individuals. Cell mediated immunity is most important resistance
against M.leprae, which is evidenced by development of protection
against leprosy after BCG vaccination. 15
Genetic factors
Many studies suggest that, among monozygotic twins if one had
leprosy, the other almost always had leprosy, but this was not seen in
dizygotic twins.25
HLA association
? Tuberculoid Leprosy DR3
? Lepromatous Leprosy DQ126
Familial Clustering
The occurrence of Leprosy is more in family clusters. The risk of
a person developing leprosy is 4 times higher when the leprosy contacts
11
are in neighbourhood; the risk is increased to 9 times if the contact is
within immediate household and even higher if they are
multibacillary.27, 28
3.  ENVIRONMENTAL FACTORS
     The risk of transmission is more in humid conditions, because
humidity favours the survival of M.leprae.The bacilli remain viable in
moist soil at room temperature for 46days.29
4.  SOCIAL FACTORS30
? Overcrowding
? Lack of education
? Poor personal hygiene
? Lack of ventilation
TRANSMISSION FACTORS
Source of infection: 31
The only source of infection is a leprosy patient. All patients but
only those capable of discharging bacilli from their body are known as
infectious or open cases belonging to lepromatous pole. On the other
12
hand, patients unable to shed bacilli are known as non-infectious or
closed cases belonging to tuberculoid pole.
Portal of exit
Skin and nasal mucosa are main portal of exit of M.leprae, the
latter is most important one. 32 Other  portal  of  exit  are  breast  milk  and
female genital mucosa.33
Portal of entry
Respiratory route and broken skin are the two main portal of
entry. Bacilli may also enter through gastrointestinal tract and as
transplacental transmission.38
Mode of transmission:15,31
? Inhalation( Droplet infection) – main mode of transmission
? Skin to skin contact
? In utero transmission
? Ingestion of Breast milk
? Inoculation following trauma
? Transmission through insects
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INCUPATION PERIOD
The minimum incubation period reported is as short as a few
weeks and this is based on the very occasional occurrence of leprosy
among young infants. The maximum incubation period reported is as
long as 30 years. However, average incubation period is 5 – 7 years.15
VACCINATION
Prevalence of leprosy is 2 times more in non-vaccinated children
than vaccinated children. BCG vaccination provide 50% protection
among contact children.35
IMMUNOLOGY
The clinical manifestations of Leprosy are highly influenced by
the immune response of the subject against M.leprae. Immune response
of the host was first pointed out by Mitsuda in 1954, he showed that
intradermal injection of killed bacilli led to a skin reaction 3-4 weeks
later with erythema and swelling at the site. Such reaction was observed
only in Tuberculoid patients and not in Lepromatous patients. This
reaction was indicating that the inflammatory response was dependant
on host immune response.36
14
Later, Dharmendra showed that a lipid free soluble factor from
the bacilli also produced a reaction in the shorter time period of 48- 72
hours.36
Mycobacterium leprae is an obligate intracellular parasite that
grows inside macrophages and Schwann cells. In addition to
macrophages and Schwann cells, other antigen presenting cells like
dendritic cells, langerhans cells and keratinocytes play an important role
in the presentation of  M.leprae antigens to T helper cells for induction
of immunity in the host.
The immunity in leprosy can be classified into: cell-mediated and
humoral immunity. Cell-mediated immunity, expressed by T cells, is the
determining factor in restricting the growth of bacilli and is responsible
for building resistance against infection. In advanced stages of the
disease, infection leads to extensive B cell proliferation, resulting in a
state of increased humoral immunity with high antibody titer.
SPECTRAL MANIFESTATION OF THE DISEASE
Leprosy manifests in various forms depending on the host
immunity. The two poles are the tuberculoid (TT) and lepromatous (LL)
types. Towards the TT pole, the host macrophages are able to kill
M.leprae, whereas towards the LL pole M.leprae grows abundantly in
15
these macrophages. There is an inverse co-relationship between the
bacterial index/antibody levels and CMI in the spectral manifestation of
the disease.
Ridley and Jopling classification was based on clinical,
histological, immunological, and microbiological parameters and
classified into the following five forms: TT, borderline tuberculoid
(BT), midborderline (BB), borderline lepromatous (BL) and LL. In
addition to these forms, there is an early stage of the disease, designated
as indeterminate leprosy, presenting as vague anaesthetic patches, in
which only a few inflammatory cells were seen.37
HUMORAL IMMUNITY
SPECIFIC ANTIBODY RESPONSE
levels of all the immunoglobulins (IgG, IgA, IgM and IgE) were
seen  in LL patients than in normal or TT individuals.38
Many autoantibodies were produced in Lepromatous leprosy
patients like Cryoglobulin, Rheumatoid factor, C- reactive protein and
false positive biological test for syphilis due to cardiolipin. These
antibodies are not seen in Tuberculoid cases.
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      The cell wall of Mycobacterium leprae protects against these
specific antibodies.
       Specific serological assays such as phenolic glycolipid- (PGLI)
based enzyme linked immunosorbent assay (ELISA)39 and 35kDa based
competitive inhibition assay were useful in monitoring patients under
treatment and correlate well with their BI.40,41 These are also useful in
diagnosing cases of relapse. Although these tests are positive in 90% to
100% of BL/LL forms,  they are not  able to identify more than 40% to
60% of the cases of TT/BT leprosy, and therefore are not useful in
diagnosing early leprosy.
      Recently, a test developed as ML-Flow test has been claimed to
be useful in diagnosing incubating leprosy in a household contact
population in Thailand.42
ANTIBODIES AGAINST OTHER ORGANISMS
Lepromatous patients often show high antibody levels against
antigens of Candida albicans, Salmonella typhae43 and tetanus toxoid. In
the lepromatous stages not only are the antibody levels to M. leprae
raised, but antibodies to other opportunistic organisms are also
increased, indicating a state of an over all activation of B cells. But, the
17
humoral immunity does not play any role in protecting the host against
M. leprae infection.
CELL MEDIATED IMMUNITY
T-cell mediated immunity is protective immunity in leprosy. In
lepromatous  leprosy,  there  is  unlimited  growth  of  M.  leprae   in  skin
tissue, nerves and mucous membranes due to the selective
unresponsiveness (anergy) of the T lymphocytes to M. leprae. A
generalized depression of CMI in LL was observed. In the peripheral
blood of LL patients, T cells are neither reduced in number, nor are
there any changes in CD4+/ CD8+ T cell ratios.44 These observations
prove that there is no generalized depression of the T cell immunity,
even in the advanced stages of the disease.
The specific CMI response has been determined  by assessing
skin delayed type of hypersensitivity(DTH) in patients. Although the
lepromin test is not a diagnostic test, it has considerable prognostic
value and provides confirmatory evidence for classification of the
disease.45 The test is usually strongly positive in most TT/BT patients. It
is negative in BL/LL patients, but tends to become positive during a
reversal reaction. In contrast, TT/BT patients during downgrading
reactions may show a negative reaction.
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T-LYMPHOCYTES
T-Lymphocytes count is reduced in all type of leprosy. Reduction
is maximum in Lepromatous patients and minimum in Tuberculoid
patients.
B-LYMPHOCYTES
There is increase in absolute number of B-Lymphocytes.
MACROPHAGES
Failure of macrophages to cope effectively with M.leprae is a
main characteristic feature of Lepromatous leprosy. This is due to
failure of T-cells to respond against M.leprae antigens and to secrete the
macrophage activating lymphokines.
      Macrophages from LL patients showed alteration in the surface
property after phagocytosis of  bacilli and unable to process the
M.leprae resulting in inability to initiate the cell mediated immunity.
CLASSIFICATION46,47
DANNIELSSEN AND BOECK(1848)
1. Nodular
2. Anesthetic
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NEISSER (1903)
1. Lepra tuberosa
2. Lepra cutanea
3. Lepra nervorum
PAN AMERICAN (1946)
1. Tuberculoid
2. Lepromatous
3. Un characteristic
MADRID (1953)
1. Lepromatous type(L)
? Macular
? Diffuse
? Infiltrated
? Nodular
? Pure neuritic
1. Tuberculoid type(T)
? Macular(Tm)
? Minor tuberculoid(Tt)
? Major tuberculoid(TT)
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? Pure neuritic(Tn)
2. Indeterminate group(I)
? Macular(Im)
? Pure neuritic(In)
3. Borderline group(B)
? Infiltrated
? (Others?)
REVISED INDIAN CLASSIFICATION(1981)
1. Tuberculoid
2. Borderline
3. Lepromatous
4. Indeterminate
5. Pure neuritic
RIDLEY AND JOPLING (1962) 48
1. Tuberculoid (TT)
2. Borderline tuberculoid(BT)
3. Borderline Borderline(BB)
4. Borderline Lepromatous(BL)
5. Lepromatous(LL)
21
WHO CLASSIFICATION(1998)
1. Paucibacillary single lesion leprosy(SLPB)
2. Paucibacillary leprosy(PB)
3. Multibacillary leprosy(MB)
PB
? 1– 5 skin lesions
? No nerve / only one nerve
? Skin smear negative at all sites
MB
? 6 and above skin lesions
? More than one nerve irrespective of number of skin lesions
? Positive skin smear at any site
CLINICAL FEATURES
There is wide variation in the clinical presentation of leprosy; in
some persons the disease involves only one peripheral nerve or causes a
single skin lesion, while in others it produces countless nodules and
other types of skin lesions, with polyneuritis and damage to vital organs,
such as eyes, larynx, bones and bones.These clinical presentations are
depends on the immune status of an individual.49
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CARDINAL SIGNS 50
1.  Hypopigmented or erythematous skin lesion with definite loss /
impairment of sensation
2.  Thickening of peripheral nerves with sensory impairment
3.  Skin smear positive for acid-fast bacilli
1.  SKIN LESIONS
Skin lesions may be single or multiple approximately 90% of the
leprosy patients had skin lesions and 79.5% had skin lesion only.51
Hypopigmented or erythematous patches / plaques are the most
common presentations in leprosy patients, along with sensory loss is
specific for leprosy. Skin lesions should be examined for number, size,
shape, margin, surface, symmetry, cutaneous nerves over the patch and
sensation, includes temperature, light touch and pain.
         The specificity of the diagnosis based on this is reduced in
multibacillary cases because the lesions can be less distinct and less
anesthetic. The sensitivity of this single criteria was 70% for all patients,
almost 30% of leprosy patients may be missed.52
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2.  ENLARGEMENT OF PERIPHERAL NERVES
Leprosy is one of the most common cause of nerve enlargement.
The most commonly involved nerves are superficial nerve trunks; ulnar,
common peroneal and greater auricular are frequently affected in that
order. Other nerves like median, radial, posterior tibial, facial and
cutaneous nerves like radial cutaneous, supraclavicular, supraorbital and
sural nerve are also felt.
Apart from the nerve trunks and the cutaneous nerves there may
be enlargement of superficial nerves supplying the macule is of great
diagnostic significance,more common in tuberculoid patch.
While examining the nerves following features are observed:
? No. of nerves enlarged
? Size of the nerves
? Symmetrical appearance
? Tenderness
? Extent of enlargement
? Nodular thickening or abscess along the course
       False Positive findings may occur because of non-specific
enlargement of nerves seen in heavy manual workers and other disease
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conditions like neurofibromatosis, amyloidosis. To improve the
specificity of the diagnosis of leprosy, besides thickened nerves, one
other diagnostic sign such as typical skin lesion with sensory
impairment is recommended.53
3. SKIN SMEAR
This is more specific cardinal sign for leprosy with the specificity
of 100%.
SITES: Earlobe is the most common site, as it yield maximum
bacilli. Other sites are forehead, cheek, chin, arm, thigh, buttock and
from the patch. At early stage bacilli is demonstrated from nasal smear
and pulp of fingers.16,54
METHODS: There are two methods of skin smear technique.
They are snip method and slit method. In snip method small portion of
skin is removed and crushed before staining. In slit method, the ear lobe
is cleaned with spirit and then is pinched tightly between thumb and
index finger for few minutes. An incision is made measuring 5mm in
length and 3mm in width by using Bard Parker blade(No.15). Then
scraping is taken from the cut surface. A smear is made on the glass
slide with a diameter of 0.7 to 1 cm.16
25
    The slides are stained by Ziehl-Nielsen’s technique. Following
indices are noted by microscopic examination of slides.
INDICES16
A. Bacterial Index(BI)
     This indicates the number of bacilli seen in an average microscopic
field. Minimum of  atleast 25 microscopic fields are examined. In this
method both live and dead bacilli are counted.The index is recorded as
follows:
6+ is Many clumps of bacilli in an average field(over 1000)
5+ is 100 – 1000 bacilli in an average field
4+ is 10 – 100 bacilli in an average field
3+ is 1 – 10 bacilli in an average field
2+ is 1 – 10 bacilli in 10 fields
1+ is 1 – 10 bacilli in 100 fields
b.  Morphological Index(MI)
     In this living bacilli are counted after counting 200 bacilli and given
as percentage.
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Features of live bacilli are:
? Parallel surface
? Rounded ends
? Uniform staining.
MI is more specific than BI.
c.SGF Index
Solid, Fragmented and Granular index. The value is:
2, if they are numerous
1, if they are few(1-20%)
0, if less than 1%
EARLY SIGNS OF THE DISEASE
? Hypopigmented / erythematous, anesthetic / hypoesthetic skin
lesion.Tuberculoid lesions are well defined hypopigmented/
erythematous anesthetic patch/ plaque. Early lepromatous lesions
are vague, ill defined coppery or hypopigmented
? Numbness or feeling of pins and needles or crawling of ants or
tingling sensation / weakness in fine movements.
? Burns resulting from contact with hot objects.
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? Appearance of  spontaneous blisters and ulcers.
? Rarely features of reactions like fever, joint pain,erythematous
tender skin lesions and edema of hands and feet.
Other features should be examined are:
? Ear lobe infiltration
? Madarosis
? Bilateral gynaecomastia
? Bilateral pedal edema
? Hepatosplenomegaly
? Lymph nodes
? 5th  and  6th  cranial nerves for lagophthalmos and corneal
sensation
? Muscle weakness
INDETERMINATE LEPROSY
In 20 to 80% of patients intermediate leprosy is the first
presentation of the disease. It is developed before the host develops
immune response to M.leprae, which is recognized only by nonspecific
defense mechanisms .55
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This type is  more common in children, skin lesions consist of
medium to large sized hypopigmented  patch, often seen on the external
aspect of thigh , face, extensor aspects of  limbs with vague edges and
some loss of sensations. Hair growth and nerve functions are rarely
affected. Occasionally dryness and wrinkles may be seen over the
lesion. Nerve thickening is not commonly seen, but sometimes
thickened. Lepromin test may be strongly positive or weakly positive or
negative.56,57
Skin biopsy is done to confirm the Indeterminate leprosy. AFB
are not usually demonstrable, but occasionally can be demonstrated
within cutaneous nerves in biopsy.
This type of  leprosy may undergo self healing. About 30% of
indeterminate type may progress into determinate type, especially
towards lepromatous pole. Progression towards tuberculoid pole is
indicated by increased anesthesia and well defined margin , lepromatous
pole is indicated by appearance of multiple new lesions. The prognosis
with treatment is good, lesions heal without any neurological or
reactional sequelae.
29
TUBERCULOID LEPROSY(TT) 49, 55, 58
Tuberculoid leprosy is a stable and benign type of leprosy;
Clinically presents as well defined erythematous elevated lesions with
involvement of peripheral nerves. Nerve involvement is usually
unilateral and asymmetrical, it occurs due to extension of  bacilli from
or through cutaneous nerve branches. This may present as purely neural
with pain and swelling of nerves, tingling sensation, loss of sesation,
muscle weakness and paralysis.Alternatively skin lesions may appear
without nerve involvement.
The skin lesions are usually single but may be up to three in
number , often eythematous plaques, less commonly hypopigmented
macules.The typical skin lesion is well defined , raised and a tendency to
central flattening. The surface is dry, anaesthetic, hairless and
sometimes scaly with size may be over 10 cms in diameter.
The skin lesions are usually appear on the face, buttocks, lateral
aspect of  extremities and scapula. The dryness and sweat loss over the
lesion is due to autonomic nerve damage in the lesion. Another
characteristic feature is cutaneous nerve thickening which is supplying
the affected area and palpated near the margin of the lesion. Usually
single nerve trunk is thickened which may be in the vicinity of skin
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lesion for example a thickened ulnar nerve if the lesion is over the
forearm . Nerve thickening may be smooth or irregular and rarely cystic
swelling of nerve and calcification may occur. On slit skin smear
examination no AFB is seen and strongly positive Lepromin test.
Tuberculoid leprosy is subdivided into major and minor
tuberculoid forms.59
Major tuberculoid
Lesions are very large and numerous with well defined margin .
They are erythematous, uniformly raised plaques with severe nerve
involvement.The lesions are frequently seen over the face and also
invade the immune zones like scalp, axilla, palms and soles. Cutaneous
nerves are often enlarged and thickened nerves may persist for long time
even after the patch has regressed.
Minor tuberculoid
The skin lesions are usually small, hypopigmented and
moderately elevated at the margin. The characteristic papules are seen at
the periphery which proceed to rapid clearing. Usually this type is not
associated with nerve enlargement, cutaneous nerve in vicinity of skin
lesion may be enlarged.
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Tuberculoid leprosy may heal itself even without treatment, so the
prognosis is good. Rarely subpolar tuberculoid lesions may downgrade
into next spectrum. The anesthesia over the lesion may persist even after
treatment.
Nodular leprosy in children is a benign clinical variant of
tuberculoid leprosy that affects the breast feeding infants and children.
This is considered to be a manifestation of allergy and congenital
immunity to M.leprae. Lesions are characterised  by indurated nodules,
papulo nodules, wheal like lesions, macules, solitary infiltrations and
lichenoid lesions usually over the cheeks, limbs and buttocks. They may
resolve spontaneously without any nerve damage or deformity.
BORDERLINE LEPROSY
Borderline leprosy is also known as dimorphous leprosy, occurs
in the spectrum between tuberculoid and lepromatous poles. Most of the
deformities and disabilities are seen in borderline leprosy. This is
immunologically unstable form and therefore may move in either
direction. Tendency  for  lepra reaction  is more in this group.
Borderline leprosy is further classified into BT, BB, BL based on
symmetry and distribution of skin lesion, border, sensory impairment,
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sweating, hair growth, nature and extent of peripheral nerve
involvement, mucosal involvement and SSS results.60
BORDERLINE TUBERCULOID(BT)
This is the most common type of leprosy. The skin lesions of BT
resembles those of tuberculoid leprosy. The number of skin lesion is
more  than  TT,  upto  10  or  more  and  asymmetrically  distributed.  They
vary in size and may cover the whole limb. The lesions are well defined
and raised in some part, flat and vague in another. Hypopigmentation,
dryness, scaling, anesthesia and pebbling are less pronounced than in
TT.
Pseudopodium may be seen, which is a small extension from the
lesion at one edge. The most characteristic satellite lesions may be seen.
Peripheral nerves are irregularly enlarged and  in asymmetrical pattern.
Nerve damage is severe and widespread. Anesthesia and motor deficit
may be found at the time of presentation. Nerve damage may progress
even after initiation of antileprosy treatment.49
BT leprosy with large hypopigmented macule and nerve
involvement is  sometimes called maculoanesthetic or low resistant
tuberculoid leprosy( macular tuberculoid). In this type the lesions are
large and asymmetrical in distribution and more commonly seen over
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face, buttock, lateral aspect of  extremities, and scapula.The lesions are
hypopigmented with well defined edges and dry, rough surface and
show some degree of loss of sweating and sensation.61
The striking feature of BT is the occurrence of type 1 reaction. If
untreated, repeated bouts of reactions may produce progressive nerve
damage, paralysis and deformity. The lepromin test is usually weakly
positive. The bacilli are scanty or absent in slit skin smear.
BORDERLINE BORDERLINE(BB) 58
This is most unstable form of the spectrum and very rarely seen.
Because of immunological instability,the disease rapidly moves into BT
or BL. Mid-borderline disease is mostly downgrades towards the
lepromatous pole if untreated. The lesions are more in number usually
more than 10 in number but not as many as lepromatous leprosy and
vary in size and shapes. The lesions may be macules, papules, plaques,
circinate lesions or nodules.
? Macules: These are hypopigmented in dark skinned people and
erythematous in fair people, numerous, less well defined and
tendency towards symmetry.
? Plaques: Erythematous or coppery.
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? Annular lesions: These are circular or oval in shape with well
defined outer and inner edges. The skin in the centre of the lesion
may be normal in colour.
? Punched out lesions: These are characteristic of BB leprosy.
Lesions are erythematous plaques with ill defined, sloping outer
edge and a punched out centre with well demarcated edge.
? Bizarre lesions: These are large lesions with geographical
appearance.
? Nodules: Occasionaly nodules over ear and chin may occur.
     Nerve damage is variable. If the patient is downgrading from BT,
nerves may be multiple and asymmetrically enlarged. If the patient is
upgrading from BL to BB, the nerves may be symmetrically enlarged.
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TABLE 1
RIDELY AND JOPLING CRITERIA
S.NO   CRITERIA      TT      BT     BB     BL      LL
01 No.of  lesions 1 - 3 4-10 11-20 >20 Multiple
02 Size Variable Variable Variable Variable small
03 Surface Very dry Dry, rough Smooth,
soft,
slightly
shiny
Smooth,
soft,
slightly
shiny
Smooth,
soft,
slightly
shiny
04 Margins Well
defined
Well to ill
defined,
mostly well
defined
Well to ill
defined
Well to ill
defined,
mostly ill
defined
Ill defined
05 Central
healing
    +      +/-       +/-      +/-    -
06 Satellite   None      +       +/-       -    -
07 Sensation in
the lesion
Absent Moderately
– markedly
diminished
Slightly -
moderately
diminished
slightly
diminished
Not
affected
08 Loss of hair
over the
lesion
Absence of
hair
Markedly
diminished
Moderately
diminished
slightly
diminished
Not
affected
09 Loss of sweat     +      +/-       +/-      +/-   +/ -
10 Symmetry     -      -       -      +/-     +
11 Local
cutaneous
nerves
    +      +/-       -      -    -
12 Peripheral
nerves
Nerves
close to the
skin lesion
are
affected
Multiple
nerves are
affected
Multiple
nerves are
affected
Multiple
nerves are
affected
Multiple
nerves are
affected
13 Other systems Not
involved
Not
involved
Not
involved
Mild Severe
14 AFB stain-BI 0 to 1+ 0 to 2+ 2+ to 3+ 4+ to 5+ 5+ to 6+
15 Lepromin test    +++      ++         +         -       -
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BORDERLINE LEPROMATOUS(BL) 61, 62
This type of leprosy shows more of  lepromatous features but still
shows some tuberculoid  features. The skin lesions are usually
numerous,  small,  vague,  round  or  oval  macules   about  2-3  cm  in
diameter. They may be erythematous, hypopigmented or shiny and starts
with vague macules,initially a small group but soon become widespread
over the trunk. The macules are smaller and not so symmertically
distributed. When the disease progress papules, nodules and plaques
may develop and some of the macules become infiltrated they appear as
‘spots of grease’ on a well paved road, especially over the face and ears.
      Peripheral nerve involvement  occur sooner than in lepromatous
leprosy. Signs of nerve damage like decreased sensation, sweating and
hair growth start soon. Eyebrows are either normal or partially involved.
Glove and stocking anesthesia are not developed till late in the disease
and eyes, oral cavity and testes are also normal.
      Many patients of BL are downgraded from BT. Associated large
lesions with some central healing  indicates downgrading of disease
from higher spectrum.Type 2 reactions are more common in BL
patients. Type 1 reactions, though uncommon, may occur in this
spectrum.
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Lepromin test is negative in this patients.
The prognosis of BL leprosy is variable.If the disease starts as BL
and treated early, the prognosis will be good. If the disease is
downgraded from BT to BL, the nerve damage and development of
reactions will be more, which further complicate neuritis and
disabilities.
LEPROMATOUS LEPROSY(LL) 49,61,62
Lepromatous leprosy occurs in persons with low level of
immunity against M.leprae. After enter into the body the bacillus
multiplies and spread in the skin, mucous membranes, nose, eyes, liver,
spleen, lymph nodes,testes and adrenals. The bacilli does not enter into
the brain and spinalcord,also not travel beyond the bifurcation of
trachea.
Glove and stocking anesthesia, corneal anesthesia, madarosis,
leonine facies and various systemic involvement are characteristic. The
skin lesions are macular, papular,infiltrated and nodular. Ulcerative
lesions may also occur rarely. The early lesions are usually small
macules, innumerable in number, widely disseminated and
symmetrically distributed. They are ill defined, erythematous and
slightly hypopigmented with shiny and moist surface. As they progress
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the entire body surface will be involved. The early lesions are not
anesthetic. Sensation is usually unimpaired in early lepromatous lesions,
but sweating may be diminished.
If the patient is not treated the skin become infiltrated, and gives
waxy appearance. Skin creases will be lost and erythema increases. The
lesions are distributed on the face over forehead, zygoma, chin and ear
lobes, and on the limbs over the cooler dorsal areas, fore arm, back of
the hand, external surface of the lower legs. There is clinical evidence of
nerve damage present in this stage. First there is loss of sensation over
dorsum of hands, forearms and lower legs. The area of sensory loss
spreads slowly until all skin is anesthetic except scalp, axillae and groin.
LL with infiltrated lesions presents as three forms: Diffuse,
Infiltrated and Nodular forms.
DIFFUSE LL
This type occurs as a result of coalescing of the numerous vague
macules. The skin looks shiny with slight infiltration. Eyebrows may
show thinning or loss of hair, but loss of eyebrow is late sign.
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INFILTRATED LL
This is more advanced stage of macular LL with visible
infiltration. The lesions will appear shiny, erythematous and raised. This
may be a sign of advancement of diffuse LL.
NODULAR LL
This type is characterised  by development of multiple nodules all
over the body. In early stage, nodule appear over the ears then the
disease advances they appear over buttocks,extremities, over joints and
genitals. This infiltrated plaques and nodules over face accentuate the
skin folds producing ‘Leonine facies’. At early stage the nodules are
mobile in the subcutaneous tissue, but later they are fixed and liable to
ulcerate.
There is gradual onset of sensory and autonomic nerve damage in
the cooler parts of the body, it may be difficult or impossible to find
clinical signs of damage to the large peripheral nerves until the disease
is well advanced. The peripheral nerves first become enlarged and firm,
then hard and fibrosed, at sites of predilection, symmetrical. The
muscles of hand and feet are affected directly as well as through the
peripheral nerves. So, muscle weakness of the hands appear early in
disease. The peripheral anesthesia may be extensive and is accompanied
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by anhidrosis with compensatory hyperhidrosis of face, trunk and
axillae.
Hair is lost in all lesions, especially over the face. Scalp hair
usually spared. Very rarely in advanced disease, scalp may be involved,
there may be residual hair growing only over the course of  the arterial
supply to the scalp called ‘Leprous alopecia’.
Nail growth may be affected late in the course of disease. Nail
plate become thin and lusterless, shrunken, narrowed, ridged and
curved. The relevant digits are narrowed because of bone atrophy and
retain the nail in a shrunken form.
Nasal mucosal involvement is seen in 80% and carries a high risk
of infectivity. Nasal symptoms may occur earlier than appearance of
skin lesions. Patients may develop nasal stuffiness or block,
mucopurulent discharge and epistaxis. The mucosa of inferior turbinate
and nasal septum may be yellow, swollen and covered with crust. At late
stage, destruction of nasal cartilage and perforation of nasal septum will
produce nasal collapse. Patient rarely may develop anosmia, due to
involvement of olfactory nerve. Nose blows are full of bacilli.
Involvement of larynx is a late manifestation and it may be
fibrotic form or ulcerative form. This causes hoarseness of voice, stridor
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and cough. Papules and nodules may be seen over mucosal surface of
lips, palate, tongue and uvula. Palatal nodules may ulcerate and produce
perforation of hard palate. Loosening or loss of upper central incisor
teeth, along with nasal collapse is called ‘Facies leprosa’, this occurs
due to atrophy of maxillary alveolar process and anterior nasal spine.
Eye involvement may be due to, direct infiltration of eye and
surrounding tissues by bacilli or abnormal exposure of eye secondary to
involvement of fifth and seventh nerves. Ocular manifestations are
lagophthalmos, corneal anesthesia, corneal opacity, perforation, uveitis
and blindness.
Involvement of internal organs, bones, liver, spleen, lymph nodes,
kidney, adrenals and muscles may occur but testicular involvement is
common. Gynecomastia may follow testicular atrophy.
Bone and joint involvement ranges from mild tenosynovitis to
leprous osteomyelitis.
VARIENTS OF LEPROSY
1. Pure neuritic leprosy:63
      Pure  neuritic  leprosy  accounts  for  5  to  10%  of  all  patients  with
leprosy. Most of the patients are mononeuritic. This is characterized by
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area of sensory loss in the absence of skin patch with or without motor
deficit. This form of leprosy is seen most frequently in India and Nepal.
Common age group is 20 to 40 yrs.
A spectrum of TT to BT is seen in histopathology of pure neuritic
leprosy. The ulnar, median, common peroneal, posterior tibial, greater
auricular and radial nerves are involved in the order of frequency. The
cranial nerves 5th  and 7th may also be involved.
2. Lucio’s Leprosy:
Lucio leprosy is a diffuse, non nodular form of lepromatous
leprosy, almost limited to Mexico. It was first described in 1852, by
Lucio and Alvarado, and later by Latapi and Zomara in 1948. It presents
as  a  uniform  diffuse  shiny  infiltration  of  the  entire  skin  and  the
appearance of the skin is waxy and shiny and in Mexico it is referred to
as ‘Lepra bonita; Beautiful leprosy’.
    The eyelids are swollen and giving a sleepy, sad appearance.
There may be numbness and edema of the hands or feet, nasal
congestion, epistaxis, hoarseness of voice and madarosis seen; this may
be mistaken for myxedema. Development of reaction in this type of
leprosy is called Lucio phenomenon, which is characterized by multiple
purpuric lesions evolving into ulceration.64
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3. Localized Lepromatous Leprosy
     This present as a single nodule or plaque with shiny and sloping
margins. The biopsy may show a lepromatous histology and full of
bacilli. The rest of the skin is normal and SSS are negative.
4.  Lazarine Leprosy:65,66
Lazarine  leprosy is an unusual manifestation of  Borderline
tuberculoid leprosy characterized by severe ulceration, seen usually in
patients with malnutrition or other debilitating illness. These ulcers are
deep up to the tendons or bones level and shows large numbers of
bacilli. The ulceration is due to extreme cellular hypersensitivity. In
addition to antileprosy drugs steroids are necessary.
5. Autoaggressive Hanseniasis:67, 68
This is seen in lepromatous leprosy or in borderline leprosy and
the features resembling connective tissue diseases like SLE. The patients
may present with fever, anorexia, asthenia, arthralgia, weight loss,
neuralgia, photosensitivity, malar rash, erythema nodosum, and
erythema multiforme-like skin lesions.
Generalized lymphadenopathy, orchitis, epididymitis, arthritis,
nephritis, iritis, uveitis, and hepatitis may also be seen. In addition,
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patient may have antinuclear antibodies in their serum. The antigen
complexes  of  bacteria  and  autologous  tissue  stimulate  B  cells  and  also
cause dysfunction of suppressor T Lymphocytes. It responds to
thalidomide 100–300 mg/d in combination with anti-leprosy drugs.
6. Silent or Invisible Lepromatous Leprosy
There is no skin infiltration in this type and the patients  are
diagnosed incidentally when they develop nasal symptoms or peripheral
anesthesia or type 2 reaction. The slit skin smear will be positive from
all sites, but the patient may be asymptomatic.
7. Spontaneous Skin Ulceration:
Long-standing LL patients rarely may develop panniculitis like
induration of the subcutaneous tissue or muscles and ulcers. This may
occur over the anterior thigh, forearm, calf or triceps.
8. Histoid Leprosy:69-71
The term Histoid was introduced by Wade,in the year of 1960.
This is an unusual variant of LL and is characterized by cutaneous /
subcutaneous nodules and plaques on apparently normal skin with
unique histopathological features and bacterial morphology. This is
more common in males than in females and most common age group is
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10-84 years. It occurs in the patients with dapsone resistance, dapsone
monotherapy, irregular and inadequate treatment.
      The lesions are reddish, dome shaped or oval, shiny, succulent,
protuberant nodules mostly over the extensor aspects of the extremities,
buttocks, back, face and bony prominences such as around the elbows
and knees. The ears are unaffected. Occasionally, lesions may simulate
molluscum contagiosum .
      A slit skin smear shows abundant AFB occurring in clusters, but
absence of globi. The bacilli are longer with tapering ends compared to
normal M.leprae. This will be treated with MB-MDT for the duration of
two years.
PATHOGENESIS AND HISTOPATHOLOGY
     M.leprae is an obligate intracellular parasite within the
macrophages and Schwann cells. The bacilli show preference for growth
in cooler regions of the body. It still cannot be cultivated in vitro. The
G-domain of the laminin ?2 chain in the basal lamina of Schwann cells ,
?-dystroglycan and the laminin receptor are the receptor complex on the
Schwann  cells.  The  ligands  on  the  surface  of  M.leprae   which  bind  to
this complex are PGL-I and a 21 kDa surface protein.72,73
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     Nerves are the only sites where the bacilli are demonstrated in the
earliest lesion. Later the bacilli are demonstrated at the dermoepidermal
junction. As per the order of importance, the organisms are seen in
nerves, neurovascular bundles, subepidermal zone, smooth muscles,
sweat glands and their ducts.74
      In TT a vigorous cellular  response occurs to limit  the disease to
the well-defined skin patches or nerves. The lesions are infiltrated by
CD4+ T lymphocytes, which form well defined granulomas containing
epithelioid and multinucleate giant cells around dermal nerves. Cellular
immunity is confirmed by in vitro lymphocyte responses to M.leprae
antigens or by skin test reactivity. Spontaneous fluctuations in the
immune response are responsible for reversal reactions and erythema
nodosum leprosum.
      There is absence of M.leprae-specific cellular immunity in
Lepromatous leprosy, and this will causes uncontrolled proliferation of
the bacilli with extensive infiltration of the skin and nerves.
Histologically, the dermis is filled with foamy macrophages and a
scattering of CD4+ and  CD8+ lymphocytes, but absence of organized
granulomas. There is progressive reduction in cellular responses is seen
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in Borderline leprosy, which is associated with a greater bacillary load,
more frequent skin and nerve lesions.
SKIN BIOPSY 75
Importance of  skin biopsy
? To confirm the diagnosis
? To classify leprosy
? To identify the complications like reactions
? To help in the management
Site
      In indeterminate leprosy the biopsy should be taken from the middle
of the lesion, where the lesion is active. If multiple lesions are present,
the most active lesion will be selected and biopsy is taken from the edge
of the lesion.
Size
     The elliptical piece of skin with size of 1.5 cm long and 0.6 cm wide
with the depth of dermis and subcutis will be taken.
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Fixatives
? Lowy’s fixative (FMA)
? Formaldehyde(40%) - 100ml
? Mercuric chloride  -  20 g
? Glacial acetic acid  -30 ml
? Distilled water       -1000 ml
      The biopsy specimen should be kept in this solution for 2 hrs and
then transferred to 70 % ethyl alcohol, in which it can be stored for long
time. The following stains are done:
? Haematoxylin & eosin stain
? Fite-Faraco stain
? Gomari methanamine silver stain
? Immunochemical stain
? S-100 stain
      Of all these staining procedures H & E stain and Fite-Faraco
stains are most commonly used.
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FITE-FARACO STAINING PROCEDURE: 76
o De paraffinize sections with xylol and liquid paraffin
mixture (2 parts of xylol and 1 part of liquid paraffin). Two
changes of 12 min each.
o Drain,  wipe excess of  oil  and blot  to opacity.  The residual
oil helps to prevent shrinkage and injury to sections. It also
prevents removal of acid-fast material from the organisms.
o If the tissue is fixed with fixatives containing mercuric
chloride, do the additional two steps:
? Treat the section with Lugol’s iodine for 5 min and
wash in water.
? Bleach  the  sections  with  5%  hypo  (sodium
thiosulfate) for 5 min and wash in water for 5 min.
o Stain with Ziehl–Nielsen carbol fuchsin solution for 30 min
at room temperature.
o Wash in tap water until all the excess stain runs out.
o Decolorize slides individually with 5% sulfuric acid for 10
min.
o Wash in tap water for 10 min.
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o Counterstain with Harris’ hematoxylin for 15 sec.
o Wash in running water for 5 min.
o Blot and dry.
o Dip in xylol.
o Mount in gum dammar or DPX mounting medium
Hematoxylin and Eosin stained sections of skin biopsies will be
examined for
           a) Epidermal atrophy
           b) Epitheloid and Macrophage Granulomas
           c) Number and Distribution of Lymphocytes, Histiocytes and
Foam cells
           d) Infiltration of Nerves, Blood vessels and Adnexa
           e) Grenz Zone.
      Sections stained with Modified Fite’s stain will be examined for
Acid Fast Bacilli in all cases.  Histopathological findings will be graded
into Polar Tuberculoid(TT), Borderline Tuberculoid(BT), Mid-
Borderline(BB), Borderline Lepromatous(BL), Polar Lepromatous(LL)
based on Ridley and Jopling Scale.
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TUBERCULOID LEPROSY(TT) 75-78
? Epidermis is usually thin
? Rete ridges are flattened
? Subepidermal free zone (Grenz zone) is absent, which is invaded
by foci of inflammatory cells.
? Dermis shows tuberculoid granuloma which consist of collections
of epithelioid cells with few Langhans giant cells surrounded by a
well-formed rim of lymphocytes, Caseation is usually absent. The
granuloma may extend from the deeper dermis in to the papillary
layer  of  the  dermis  and  causes  erosion  of  the  epidermis  and
atrophy.
?  Epitheloid  granulomas are also seen adjacent to blood vessels,
sweat glands, hair follicles, and sebaceous glands.
? Dermal nerves are surrounded by well-formed epitheloid
granulomas with extensive destruction of nerves are seen.
Acid fast bacilli
Absent; non viable bacilli may sometimes present
BORDERLINE TUBERCULOID(BT) 74,75
? Atrophy of epidermis.
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? Clear subepidermal zone may be seen,but at some points spur
of granuloma may enter the epidermis.
? The granulomas are poorly formed and composed of collection
of epitheloid cells, Langhan’s giant cells and lymphocytes. In
early lesion the granulomas are branching and project as spur
along the neurovascular bundle.
? Nerves are swollen with granuloma and the infiltration of
lymphocytes in perineurium may cause slight lamination.
AFB stain: BI is around 0 to 2+
MID BORDERLINE (BB) 75
? Epidermis is atrophic.
? Clear subepidermal zone is seen.
? Dermis contains diffuse granuloma which consist of admixture of
almost equal number of epitheloid cells and macrophages.
Lymphocytes are less in number and scattered in granuloma.
? Giant cells are absent, this will help to differentiate it from BT.
? Usually some amount of intercellular edema is present.
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? Nerves are infiltrated by granuloma, but not completely
destroyed.There is lymphocytic infiltration and reactive
proliferation of perineurium.79
AFB: BI is 3+ to 4+
BORDERLINE LEPROMATOUS (BL)
? Atrophic epidermis is separated from the granuloma by clear
subepidermal zone(Grenz zone).
? Poorly formed granuloma is seen in dermis, which consists
predominantly macrophages with solitary clump of epitheloid
cells. Lymphocytes and plasma cells may also be seen. Some of
the macrophages may show foamy changes.
? There is concentric perineural proliferation giving rise to onion
peel appearance. Perineurium is infiltrated by many macrophages
and lymphocytes.
? Clumps of AFB are seen within the macrophages, perineural cells,
endothelial cells, Schwann cells and arrector pili muscle.
AFB stain: Plenty of bacilli with small globi will be seen.  BI is 4+ to 5+
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LEPROMATOUS LEPROSY (LL) 75
? Epidermis is thin and atrophy.
? Rete ridges are completely flattened.
?  There is clear subepidermal zone.
? Dermis shows macrophage granuloma. Initially most of the
macrophages have pink and granular cytoplasm, later in old
lesions the cytoplasm becomes foamy and vacuolated (Virchow
cells or Lepra cells).
? Focal collections of plasma cells and few lymphocytes are
distributed in the lesion.
? Cellular infiltrates are seen as a small focal cluster in early
lesions, as the disease progress these clusters merge together to
form a band of infiltrate in the dermis and may extend to
subcutaneous fat. Piling of macrophages and other inflammatory
cells lifts up the overlying skin producing plaques and nodules.
? Nerves are also infiltrated by macrophages. Reactive proliferation
of perineurium is minimal.
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AFB stain: Clumps of bacilli are seen in macrophages, perineurium,
endothelial cells, Schwann cells, arrector pili muscle, sweat and
sebaceous glands and hair follicles.
BI is 5+ to 6+
INDETERMINATE LEPROSY (IL) 75, 80, 81
These lesions are difficult to diagnose clinically, and may require
histo-pathological examination to confirm the diagnosis. The
histopathological changes are minimal and may be missed unless the
biopsy is adequate, including some amount of subcutis.
? No  significant  changes  in  epidermis  but  may  show  areas  of
atrophy.
?  The dermis may consist of a mild perivascular and periadnexal
infiltrate of histiocytes and mainly lymphocytes.
?  The dermal nerves are thickened and infiltrated by lymphocytes.
Schwann cell hyperplasia may be seen.
? The presence of AFB in any one of the following locations
confirms the diagnosis- immediately underneath the epidermis,
arrector pili muscle, nerve bundles or in a macrophage.
      A presumptive diagnosis of leprosy can be made, even in the
absence of M.leprae, if the inflammation of nerve is accompanied by
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clinical features of nerve involvement, such as sensory loss. In the
affected nerve, some fascicles may show inflammation while others may
be spared , so examination of multiple consecutive sections are
important.
      It is important to examine at least 10–15 sections before ruling out
the diagnosis of leprosy. The Fite–Faraco stain is recommended for
demonstrating bacilli in tissues.
HISTOID LEPROSY 82-84
?  Atrophic epidermis.
? There is clear subepidermal zone.
? Circumscribed lesion is usually located in deep dermis or subcutis
and is surrounded by pseudo capsule.
? The lesion is expansile in nature and consisting of  spindle shaped
histiocytes. Bacilli are arranged in parallel bundles aligned along
the long axis of  the histiocytes (Histoid habitus). These bacilli are
longer than the normal lepra bacilli.
? Presence of foci of epitheloid cells in the lesion is known as
tuberculoid contamination.
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AIMS OF THE STUDY
? To study the epidemiological aspects of Leprosy like age,
sex distribution etc.
? To study the various types of clinical presentation among
the patients
? To study the Clinico-histopathological correlation in
various spectrum.
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MATERIALS AND METHODS
      The prospective study was conducted at Outpatient Department of
Dermatology in Rajiv Gandhi Government General Hospital, Chennai- 3
for a period of one year from October 2013 to September 2014.
      A minimum of fifty patients of Leprosy belonging to all age
groups and both sexes were randomly selected and included in the study
after taking their consent. In each patients detailed history, thorough
general and local examination was done as per the standard protocol
followed for examining a patient with Leprosy. In all patients necessary
investigations and Slit  skin smear were done.  Skin biopsy was done in
all cases for histopathological study with patients consent.
INCLUSION CRITERIA
? Patients of both sexes proven to have Hansen’s who had not taken
any anti-leprosy treatment prior to visiting our OPD
? Patients who gave consent for Biopsy
EXCLUSION CRITERIA
? Patients who had already taken MDT in the past
? Patients not willing for Biopsy
? Pregnant women
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HISTORY
    Detailed history of age, sex, occupation and socioeconomic status
was taken and presenting complaints like skin lesions, numbness,
trophic ulcers and deformities were noted. In this study socioeconomic
status of patients was divided into 3 categories based on kuppusamy’s
scale.
CLINICAL EXAMINATION
      A detailed general examination was carried out in all the patients.
Local examination of skin lesions was carried out with particular
references to the number, shape, size, surface, margins, satellite lesions,
supplying nerves, sensation, sweat loss, hair loss and trophic changes.
All the peripheral nerves were palpated for enlargement and tenderness.
     The patients were clinically diagnosed as Tuberculoid(TT),
Borderline tuberculoid(BT), Borderline borderline(BB), Borderline
lepromatous(BL), Lepromatous(LL).
ROUTINE INVESTIGATIONS
      All patients were investigated routinely like Hb%, total count,
differential count, ESR, Platelet count, bleeding time, clotting time and
ELIZA for HIV.
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SLIT SKIN SMEAR
Slit smear was taken for demonstration of Acid fast Bacilli. It was
taken from 2 ear lobes and active lesion. Then the smear was allowed to
dry and fixed by passing the slide over the top of a flame. The fixed
smear was stained with Ziehl-Nielsen stain. The Bacteriological Index
(BI) was calculated according to Ridley’s scale.
PREPARATION OF REAGENTS
Carbol Fuchsin
? Basic fuchsin 2 g
? Phenol, melted 10 ml
? Alcohol 90% 20 ml
? Distilled water 170 ml
      Weigh basic fuchsin and place in an Erlenmeyer flask, then add
phenol and subsequently add alcohol and then add 10 ml of water.
Shake to mix well, then add about 20–25 ml water. Shake until all the
dye is dissolved. Then add the balance water and shake well. Filter it
and store in a labelled and tightly stoppered bottle as a stock solution.
Then fill labeled dropping bottles when needed for staining smears.
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Sulfuric Acid
? Concentrated sulfuric acid 10 ml
? Distilled water 190 ml
      Measure water and pour in an Erlenmeyer flask. Then measure
acid  and  pour  acid  slowly  down  the  side  of  the  flask  into  the  water.
Never pour water into the acid. Then rotate to mix and then shake. The
solution will become hot. When cool, pour diluted acid into a labeled
tightly stoppered bottle. Store as a stock solution. Then pour into a
labeled dropping bottle when needed for staining smears.
Acid Alcohol
? Concentrated hydrochloric acid 10 ml
? Ethyl alcohol 70% 990 ml
      Pour acid gradually into alcohol stirring to mix. Store in screw
capped labeled bottles and pour into dropper bottles as needed.
Methylene Blue
? Methylene blue 0.4 g
? Absolute alcohol 20 ml
? Distilled water 180 ml
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      Weigh methylene blue and place in a mortar. Then add 20 ml
absolute alcohol and grind to dissolve. Then add 25–50 ml water and
mix well.  Then transfer  with a pipette  to an Erlenmeyer flask and then
add the balance water. Shake well and filter. Then store in a labelled and
tightly stoppered bottle as a stock solution. Then pour into a labeled
dropping bottle when needed for staining smears.
ZIEHL-NEELSEN STAINING PROCEDURE
1.  Place the slide with fixed smears on rods over a sink.
2.  Flood with carbol fuchsin. Heat gently by passing a spirit lamp
along the underside of the slides until a cloud of steam rises. Do
not heat to boiling. Do not allow the stain to evaporate to dryness.
Steam for 15 min.
3.  Allow to cool. Wash in tap water.
4.  Flood with 5% sulfuric acid. Let it stand for 3 secs.
5.  Wash in tap water.
6.  Flood with methylene blue (for counterstaining). Let it stand for
10 secs.
7.  Wash in running water and allow to dry.
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M.leprae is a acid-fast bacilli, is seen as pink coloured rods
arranged in clumps.
HISTOPATHOLOGICAL EXAMINATION
     Skin Biopsy specimen was obtained from all clinically diagnosed
cases of Leprosy and was subjected to the following staining techniques
? Hematoxylin and Eosin stain
? Modified Fite’s stain
Hematoxylin and Eosin stained sections of skin biopsies were examined
for
? Epidermal atrophy
? Epitheloid and Macrophage Granuloma.
? Number and Distribution of Lymphocytes, Histiocytes and Foam
cells
? Infiltration of Nerves, Blood vessels and Adnexa
? Grenz Zone.
       Sections stained with Modified Fite’s stain were examined for
Acid Fast Bacilli.  Histopathological findings were graded into Polar
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Tuberculoid(TT), Borderline Tuberculoid(BT), Mid-Borderline(BB),
Borderline Lepromatous(BL), Polar Lepromatous(LL) based on Ridley
and Jopling Scale.
STATISTICAL ANALYSIS PLAN
     Datas obtained were analysed using appropriate statistical package
suggested by the Statistician.
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OBSERVATION AND RESULTS
Age distribution
     In our study, the youngest patient was 7 years old and the eldest was
65 years old.
     The maximum number of patients(52%) showing clinical activity in
this study belonged to the 21- 40 years age group whereas the least
number of patients belonged to the less than 20 years age group.
TABLE 2 : AGE DISTRIBUTION
Age Frequency Percent
0 – 20 9 18.0
21 – 40 26 52.0
MORE THEN 40 15 30.0
Total 50 100.0
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FIGURE 1: AGE DISTRIBUTION
Sex distribution
In the present study, male patients comprised 82 % and female
patients 18 % of the total patients.Male to female ratio was 4.5 : 1
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TABLE 3: SEX DISTRIBUTION
Sex distribution Frequency Percent
Female 9 18.0
Male 41 82.0
Total 50 100.0
FIGURE 2: SEX DISTRIBUTION
Occupation
      In our study maximum number of patients were coolies (22%).
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TABLE 4: OCCUPATION
Occupation Frequency Percent
Business 2 4.0
Coolies 11 22.0
Driver 3 6.0
Farmer 6 12.0
House wife 5 10.0
Labourer 8 16.0
Mechanic 2 4.0
No work 1 2.0
Painter 1 2.0
Security 1 2.0
Student 9 18.0
Tailor 1 2.0
Total 50 100.0
Next common occupation  were students (18%), labourer (16%),
Farmers (12%) and house wives (10%).
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FIGURE 3: OCCUPATION
Socioeconomic status
In the present study, 62% were from Low income group whereas
38% patients were from Middle income group. There were no patients
from High income group.
TABLE 5:  SOCIOECONOMIC STATUS
SES Frequency Percent
Low 31 62.0
Mid 19 38.0
Total 50 100.0
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FIGURE 4: SOCIOECONOMIC STATUS
Duration
Minimum duration of disease was 1 month and maximum was 10
years.
? Maximum number of patients 36 i.e., 72% in this study had the
disease duration of less than 1 year
?  Duration was between 1-5 years in 12(24%)
?  More than 5 years in 2(4%).
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TABLE 6: DURATION
Duration Frequency Percent
< 1 YEAR 36 72.0
> 5 YEAR 2 4.0
1 TO 5 YEAR 12 24.0
FIGURE 5: DURATION
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Complaints
       In  this  study  out  of  50  patients,  32(64%)  patients  had  the
complaints of hypopigmented skin lesion.
      14(28%) patients had raised lesions. Numbness & hypopigmented
lesions in 3(6%)  patients and swelling & hypopigmented lesions in
1(2%)  patients.
TABLE 7: COMPLAINTS
COMPLAINTS Frequency Percent
Hypopigmented lesions &
Numbness
3 6.0
Hypopigmented lesions&
swelling
1 2.0
Hypopigmented lesions 32 64.0
Raised lesions 14 28.0
Total 50 100.0
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FIGURE 6: COMPLAINTS
Morphology
In this study majority of patients had patches on examination
(50%). 18% of patients had nodules only.
16% had macules and patches, 8% had plaques, 4% had patches
and nodules, 2% had macules & plaques and 2% had macules &
nodules.
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TABLE 8: MORPHOLOGY
Morphology Frequency Percent
Macules & Nodules 1 2.0
Macules & Patches 8 16.0
Macules & Plaques 1 2.0
Nodules 9 18.0
Patches 25 50.0
Patches & Nodules 2 4.0
Plaques 4 8.0
Total 50 100.0
FIGURE 7: MORPHOLOGY
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Site distribution of skin lesions
      In our study among 50 patients, majority of patients had lesions
over multiple sites of body.
? 33(66%) patients had lesions over multiple sites of body
?  11(22%) cases had lesions on upper limbs
?  2(4%) on the lower limb
? 2(4%) on trunk
?  2(4%) on the head & neck.
TABLE 8: SITE DISTRIBUTION
Site Frequency Percent
HEAD & NECK 2 4.0
LOWER LIMB 2 4.0
MULTIPLE SITES 33 66.0
TRUNK 2 4.0
UPPER LIMB 11 22.0
Total 50 100.0
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FIGURE 7: SITE DISTRIBUTION
Clinical diagnosis
In our study all the patients were thoroughly examined clinically
and diagnosed.
Out of 50 cases,
? 4(12%) were diagnosed as TT
? 21(42%) as BT
? 4(8%) as BB
? 7(14%) as BL
?  14(28%) as LL
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TABLE 9: CLINICAL DIAGNOSIS
Clinical diagnosis Frequency Percentage
Tuberculoid leprosy 4 8.0
Borderline tuberculoid 21 42.0
Mid borderline 4 8.0
Borderline lepromatous 7 14.0
Lepromatous leprosy 14 28.0
Total 50 100.0
FIGURE 8: CLINICAL DIAGNOSIS
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Slit skin smear-Acid fast bacilli
In our study 26(52%) patients showed smear positivity whereas
24(48%) showed smear negativity.
1(3.8%) BT patient, 4(15.4%) BB, 7(26.9%) BL and 14(53.8%)
LL patient showed smear positivity. All tuberculoid patients were smear
negative.
TABLE 10: SLIT SKIN SMEAR – AFB
SSS-AFB Frequency Percentage
NEGATIVE 24 48.0
POSITIVE 26 52.0
Total 50 100.0
FIGURE 9 : SLIT SKIN SMEAR- AFB
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In this study 10% of smear positive patients had BI less than 3+
and 42% of patients had more than 3+ of BI.
TABLE 11: SSS- BI
BACTERIAL
INDEX
Frequency Percentage
<3+ 5 10.0
>3+ 21 42.0
Negative 24 48.0
FIGURE 10: SSS-BI
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TABLE 12: SSS-AFB AND CLINICAL DIAGNOSIS
                                                       CLINICAL DIAGNOSIS
SSS - BI TUBERCULOIDLEPROSY
BORDERLINE
TUBERCULOID
MID
BORDERLINE BORDERLINE
LEPROMATOUS
LEPROMATOUS
LEPROSY TOTAL
POSITIVE 0 1 4 7 14 26
0% 3.8% 15.4% 26.9% 53.8% 100.0%
NEGATIVE 4 20 0 0 0 24
16.7% 83.3% 0% 0% 0% 100.0%
Total 4 21 4 7 14 50
8.0% 42.0% 8.0% 14.0% 28.0% 100.0%
FIGURE 11 : COMPARISON  OF SSS-AFB & CLINICAL
DIAGNOSIS
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Histopathological distribution
 In  our  study  skin  biopsy  was  taken  from  all  the  50  patients  and
stained with     H & E stain.
? Out of 50 patients 20(40%) patients were histologically
diagnosed as BT
? 15(30%) as LL
?  8(16%) as BL
?  4(8%) as BB
?  3(6%) as TT.
TABLE 13: HISTOPATHOLOGICAL DISTRIBUTION
Histopathological diagnosis Frequency Percent
TUBERCULOID LEPROSY 3 6.0
BORDERLINE TUBERCULOID 20 40.0
MID BORDERLINE 4 8.0
BORDERLINE LEPROMATOUS 8 16.0
LEPROMATOUS LEPROSY 15 30.0
Total 50 100.0
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FIGURE 12 : HISTOPATHOLOGICAL DISTRIBUTION
Fite- Faraco stain
TABLE 14: FITE-FARACO STAIN
Fite-Faraco stain Frequency Percentage
NEGATIVE 30 60.0
POSITIVE 20 40.0
Total 50 100.0
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     Out  of  50  patients,  20(40%)   cases  showed  stain  positivity  and
30(60%) cases showed stain negativity. 5(25%) of BL and 15(75%) of
LL patients showed stain positivity. Other types were negative.
TABLE 15: FITE-FARACO STAIN & HISTOPATHOLOGICAL
DIAGNOSIS
Histopathological diagnosis
TotalFite-faraco
stain
Tuberculoid
leprosy
Borderline
tuberculoid
Mid
borderline
Borderline
lepromatous
Lepromatous
leprosy
Positive
0 0 0 5 15 20
0% 0% 0% 25.0% 75.0% 100.0%
Negative
3 20 4 3 0 30
10.0% 66.7% 13.3% 10.0% 0% 100.0%
Total
8 20 15 4 3 50
16.0% 40.0% 30.0% 8.0% 6.0% 100.0%
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FIGURE 13 :FITE-FARACO STAIN
FIGURE 14: FITE-FARACO STAIN & HISTOPATHOLOGICAL
DIAGNOSIS
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Comparison of clinical and Histopathological diagnosis
TABLE 16: COMPARISON OF CLINICAL &
HISTOPATHOLOGICAL DIAGNOSIS
CLINICAL
DIAGNOSIS
HISTOPATHOLOGICAL DIAGNOSIS
TT BT BB BL LL
       TT  (4) 75% (3) 25% (1) 0% (0) 0% (0) 0% (0)
 BT  (21) 0% (0) 85.7% (18) 14.3%
(3)
0% (0) 0% (0)
BB  (4) 0% (0) 25% (1) 25% (1) 50% (2) 0% (0)
BL  (7) 0% (0) 0% (0) 0% (0) 71.4% (5) 28.6% (2)
 LL  (14) 0% (0) 0% (0) 0% (0) 7.1% (1) 92.9% (13)
Clinico-histopathological agreement was seen in 40 (80%) cases
and disagreement in 10 (20%) cases.
Out of 4 patients clinically diagnosed as TT, 3(75%) patients had
histopathological correlation. Out of 21 patients clinically diagnosed as
BT, 18(85.7%) patients had histopathological correlation.Out of 4
patients clinically diagnosed as BB only one patient had histological
correlation, out of 7patients clinically diagnosed as BL, 5 patients had
histopathological correlation, out of 14 patients clinically diagnosed as
LL, 13 patients had histopathological correlation.
86
FIGURE 15: COMPARISON OF CLINICAL &
HISTOPATHOLOGICAL DIAGNOSIS
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DISCUSSION
In  the  present  study,  Ridley-Jopling  classification  was  used  to
classify leprosy histopathologically in all cases. Indeterminate leprosy
was not included for analysis. Histoid leprosy is considered as a variant
of Lepromatous leprosy and it was included in LL spectrum.
Age distribution
In the present study more number of patients belong to the age
group of 21-40 years(52%).
In a study done by Moorthy BN et al 85, majority of patients were
between 20-29 years (20.70%).
Singh et al 86, found the disease in 48% of patients belonging to
age group of 21- 40 years.
Santaram and Porichha87 found majority of patients were 21- 40
years.
Similarly Jindal et al88 and Samuel et al89 found  the  disease  in
48% of patients belonging to the age group of 21- 40 years.
Thus the age incidence in the present study correlates well with
the other studies. The disease is more common in this age group because
of their mobility and increased opportunity for contacts.
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Sex distribution
In  the  present  study  82%  of  patients  were  males  and  18%  were
females. Similarly Santaram and Porichaa found the disease in 80% of
males.
Singh et al86 found the disease in 69% of males.
Similarly Moorthy et al85,  Gridhar  M  et  al 90 and Nitesh Mohan
et al 91 found the disease to be more common in males.
Comparison of sex in various studies
Authors -  Males (%)
Santaram et al 87 - 80
Singh et al 86 - 69
Moorthy et al 85 - 65.05
Bhushan et al 92 - 72.34
Mathur MC et al 93 - 53.8
Gridhar M et al 90 - 77.6
Nitesh Mohan et al91- 72.10
Present study - 82
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      The result of the present study is close to the above mentioned
studies with regard to the sex. This disease is more common in males
because of their outdoor works and higher chances of getting infection.
Occupation
In the present study majority of patients were coolies(42%).
Next common occupation  were students (18%), labourers (16%),
Farmers (12%) and house wives(10%).
Similar observation was noted in the study by Ramanjanayalu94.
In that 41% of patients were coolies.
Choudhuri et al 94 90% of patients were agricultural workers.
Thappa et al95 found manual labourers comprised 53.9% of patients.
This is due to low economic status among people in manual work.
Socioeconomic status
In the present study 62% of patients were from low income group
and 38% of patients were from middle income group.
Similar observations were made by Mutakar97 and Chhabriya
et al98 , the majority of patients belonged to low income group.
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      Singh et al86 found the disease in 57% of patients belonging to
low socioeconomic status.
      Thus the disease is common in people from low socioeconomic
status. This is because of the fact that low income group is always
associated with illiteracy, over crowding, malnutrition and lack of
personal hygiene, which are the important factors in acquisition of the
disease in case of leprosy.
Duration
      The duration of illness in the present study was less than 1 year in
72% of patients, 1-5 years in 24% and more than 5 years in 4% of
patients.
Similarly Ramanjanayalu 94 found the duration of illness was less
than 6 months in 54% of patients, 1-5 years in 24% and 6-11 months in
17% of patients.
Wim et  al99 , found the duration was up to 6 months in 30% of
patients, 7-12 months in 32%, 13-24 months in 17%, 25-36 in 9.3%, 37-
60 months in 6.3% and more than 60 months in 5.4%.
Thus most  of  the patients  had the illness for  the duration of  less
than 1 year. This is because of the patients present to the hospital earlier.
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Complaints
In this study out of 50 patients, 32(64%)  patients had the
complaints of Hypopigmented skin lesion.
14(28%) patients had Raised lesions, Numbness &
Hypopigmented lesions in 3(6%) patients and swelling &
hypopigmented lesions in 1(2%) patients.
Similarly Nitesh Mohan et al91 found that most common clinical
presentation was hypopigmented patch (61.58%) followed by
erythematous plaque or nodule (38.42%). This also correlated well with
study done by M Gridhar et al90 and Ocampo and Francisco.
Hypopigmented anesthetic skin lesion is one of the cardinal sign
of leprosy.
Morphology
In this study majority of patients had patches on examination
(50%) . 18% of patients had nodules only.
16% had macules and patches, 8% had plaques, 4% had patches
and nodules, 2% had macules & plaques and 2% had macules &
nodules.
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There are no many available studies to compare this parameter.
Site of lesion
In the present study 66% of patients had the lesions over multiple
body sites and 22% had the lesions on upper limbs.
But in the study done by Nitesh Mohan et al91 , 34.21% of
patients had the lesion on upper limbs, 21.05% of patients had on head&
neck site and 15.79% on multiple sites.
There are no many available studies to compare this parameter.
Clinical diagnosis
In the present  study,  out  of  50 patients  ,  42% were diagnosed as
BT, 28% as LL, 14% as BL, 8% as TT and 8% as BB.
Nitesh Mohan et al 91 found BT in 45.26%, LL in 23.68%, BL in
13.68%, TT in 7.89% and BB in 2.12% of patients.
Similarly Ramanjanayalu94 and Zhongdong 100 found that majority
of patients had BT.
Jindal et al88 found  LL  in  33%,  BT  in  28%,  BL  in  23%,  TT  in
5.5% and BB in 4% of patients.
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Vara and Marfatiya101 found BT in 36%, LL in 52%, TT in 13%,
BB in 9% and BL and pure neuritic in 8%.
Thus the results in the present study correlate well with other
studies and most common clinical type was Borderline tuberculoid.
SSS-Acid fast bacilli
In the present study 52% of patients showed smear positivity and
48% of patients showed smear negativity.
Smear positivity was less than 3+ in 10% of patients and more
than 3+ in 42% of patients.
All  BB,  BL  and  LL  patients  were  smear   positive  and  all  TT
patients were smear negative. 3.8% of BT patients only smear positive.
Ramanjanayalu94 found overall positivity in 39% of patients and
negativity in 60% of patients.
Vara and Marfatiya101 found positivity in 38% of patients.
In the study of Vara102, smear positivity was less than 3+ in 28%
of patients and more than 3+ in 18% of patients. Smear negativity in
54% of patients.
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The smear positivity in the present study is more than above
mentioned studies. This is probably because of clinical typing of
patients.
Histopathological distribution
In our study 40% of patients histopathologically diagnosed as BT
patients, 30% as LL, 16% as BL, 8% as BB and 6% as TT.
Similarly Nitesh Mohan et al91 found 44.4% as BT, 19.05% as
LL, 14.8% as IL, 12.7% as BL, 7.4% as TT and 1.6% as BB.
In  the  study  of   Manandhar  et  al103 , 40% of patients
histopathologically diagnosed as BT.
Thus histologically, the common classification made was
Borderline tuberculoid.
Fite-Faraco stain
Fite-Faraco stain was positive in 40% of patients and negative in
60% of patients.
In that positive patients, 75% were belonging to LL and 25%
were belonging to BL.
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    Manandhar  et al103 found positive in 25% of patients. In
contrast to our study, various studies reported better demonstration of
AFB in biopsy than in slit skin smear.
Bhusan  P  et  al92 . found significant number of positive cases in
biopsy which constituted 65 (46.09%) cases while SSS positive only in
43 (30.05%) cases.
AFB are better demonstrated  usually in biopsies than in slit skin
smear due to presence of AFB in deep reticular dermis where they
remain inaccessible to SSS.
Clinico-histopathological correlation
In our study skin biopsy was done in all 50 patients.
Clinico-histopathological agreement was seen in 40 (80%) cases
and disagreement in 10 (20%) cases.
Out of 4 patients clinically diagnosed as TT, 3(75%) patients had
histopathological correlation.
Out of 21 patients clinically diagnosed as BT, 18(85.7%) patients
had histopathological correlation.
Out of 4 patients clinically diagnosed as BB only one(25%)
patient had histological correlation.
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Out of 7 patients clinically diagnosed as BL, 5(71.4%) patients
had histopathological correlation.
     Out of 14 patients clinically diagnosed as LL, 13(92.9%) patients
had histopathological correlation. There was complete agreement
between the clinical and histopathologic diagnosis in 80% of the cases.
Comparative study in clinico-pathological correlation by different
authors.
Various studies - Clinicohistopathological
correlation(%)
Manandhar et al103 - 45.33
Nitesh Mohan et al91 - 5.54
Sehgal VN et al104 - 33
Vargas-ocampo F et al 105 - 42.9
Mitra K et al106 - 57.16
Pandya AN et al107 - 58
Moorthy BN et al85 - 62.63
Kalla G et al108 - 64.7
Ridley DS et al109 - 68.3
Jerath VP et al110 - 68.5
Bhatia AS et al111 - 69
Kar PK et al112 - 70
Nadkarni NS et al113 - 81.8
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      In the present study, Maximum concordance was observed in LL
type of leprosy, which was similar in studies by Mathur MC et al93,
Gridhar M et al90 and Moorthy et al.
TABLE 17: CLINICO-PATHOLOGICAL CORRELATION IN
VARIOUS SPECTRUM IN VARIOUS STUDIES
Types of
leprosy
Mohan
et al
Manandhar
et al
Moorthy
BN et al
Nadkarni
NS et al
Kar
et al
Kalla
et al
Jerath&
Desai
Present
study
TT 71.93 24 46.15 97 87.5 75.6 74.5 75
BT 79.76 63.15 66.66 95 60.9 44.2 64.7 85.7
BB 66.67 0 50 89 54.5 37 28.5 25
BL 66.67 57.14 70 87 53.8 43.7 53.8 71.4
LL 97.22 57.14 80 98 71.4 76.7 61.5 92.9
IL 50 0 20 - 81.2 - 88.8 -
     Different studies observed highest percentage of
clinicopathological correlation of  lepromatous leprosy and tuberculoid
leprosy in their studies and showed least clinic-pathological correlation
in midboderline lepomatous leprosy.
In  contrast  to  our  study,  Nayak  SV  et  al114 study showed
maximum correlation in midborderline (100%).
Ridley and Jopling found complete agreement between clinical
and histopathological types in 68.3%37.
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There was a minor disagreement (disagreement in one group) in
10 (20%) cases and no major disagreement (more than one group).
Ridley and Jopling, found minor disagreement in 21 patient (25.6%),
major disagreement in 5 patient (6%).
      The variation in different studies may be due to different criteria
used to select the cases and difference in number of cases of each type.
Various factors also influence the histopathological diagnosis such as
differences in sample size, choosing the biopsy site, age of the lesion,
immunological status of the patient at the time of biopsy.
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 SUMMARY
? Majority of patients (52%) belongs to the age group of 21- 40
years.
? Male patients comprised 82% and female patients were 18%.
? Majority of patients were coolies (42%). Next common
occupation were students (18%), labourers (16%), Farmers (12%)
and house wives (10%).
? 62% of patients were from Low socioeconomic group and 38% of
patients from Middle income group.
? 72% of  patients had the disease duration of less than 1 year, 24%
had the duration between 1-5 years and more than 5 years in 4%
of patients.
? 32(64%) patients had the complaints of Hypopigmented skin
lesion. 14(28%)  patients had  Raised lesions, Numbness &
Hypopigmented lesions in 3(6%) patients and swelling &
hypopigmented lesions in 1(2%) patients
? Majority of patients had patches on examination (50%) , 18% of
patients had nodules only.
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? 66% patients had the lesions over multiple sites of the body, 22%
cases had the lesion on upper limb, 4% on the lower limb, 4% on
the trunk and 4% on the head & neck.
? Borderline tuberculoid was the most common clinical
presentation comprising of 42%.
? 52% of patients showed Acid fast stain positivity and 48% were
smear negative. 1(3.8%) BT patient, 4(15.4%) BB, 7(26.9%) BL
and 14(53.8%) LL patients showed smear positivity.
? Out of 50 patients 40% patients were histologically diagnosed as
BT, 30% as LL, 16% as BL, 8% as BB and 6% as TT.
? 40% of patients showed Fite-Faraco stain positivity in biopsy
specimen. 5(25%) of BL and 15(75%) of LL patients showed
stain positivity.
? Clinico-histopathological agreement was seen in 80% of cases
and disagreement was seen in 20% of cases.
Out of 4 patients clinically diagnosed as TT, 3(75%) patients had
histopathological correlation. Out of 21 patients clinically diagnosed as
BT, 18(85.7%) patients had correlation. 25% of BB patients had
clinichistopathological correlation, 71.4% of BL and 92.9% of LL
patients had clinicohistopathological correlation.
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CONCLUSION
In our study,
? The higher incidence in the age group 21-40 years is because of
their mobility and increased contact with the infective persons.
? The incidence was higher in males because of their more physical
activity and thus more chances of getting infection. Because of
ignorance and hesitation to come forward to treatment, low
incidence is seen in females.
? Majority of patients were coolies.
? Most of the people affected were from low socioeconomic group.
? The duration of illness was less than one year in majority of
patients.
? Most common complaint was hypopigmented skin lesions.
? The higher  number of patients were Borderline tuberculoid. This
is because, these patients come early for the treatment because of
its neurological symptoms.
? SSS-AFB positivity was found in 52% of patients but Fite-Faraco
stain of skin biopsy showed positivity in 40% of cases.
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? Clinico-histopathological correlation was seen in 80% of the
patients. Maximum correlation was observed in Lepromatous
leprosy. So, LL patients can be diagnosed clinically.
     In conclusion it can be said Leprosy still continues to be a domestic,
national, global burden and is present in different clinico-pathological
forms.
     Many cases can be diagnosed clinically; especially Lepromatous pole
of the disease, however, other types of Leprosy pose a significant
problem in clinical diagnosis. Histopathological  examination of the
lesions confirms the exact subtype of the disease and facilitate the
institution of accurate mode of therapy. So, correlation of clinical and
histopathological features along with bacteriological index is more
useful for accurate typing of leprosy than considering single parameter
alone.
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14 Sathyavanan 38 Male Driver Mid 1Yr Raised lesions Nodules Multiple
 Face
B.arms
B.forearms
Chest
B.thighs
B,legs Y
Face Ear
lobe Y Y G & S
B.GA
B.UL
B.LP
R. Claw
hand LL 5+ LL P
15 Amirtham 50 Female Coolie Low 10Yrs
Loss of
sensation
Hypo. P Patches 4
Back
L.forearm Y Y Y Y Y Y Y
L.UL
L.RC BT 0 BT N
16 Rathna velu 36 Male Business Low 5Yrs Hypo. P Patches 5
Back
L.thigh
L.leg Y Y Y Y Y Y Y Y
B.UL
B.LP BT 0 BT N
17 Paul raj 30 Male Mechanic Low 1Yr Raised lesion Nodules Multiple
Chest back
Abdomen
B.arms
B.forearms
B.legs Y Y Y Y Y
R.UL
R.RC LL 4+ BL P
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18 Sujatha 30 Female Labourerer Low 1Yr Hypo. P Patches 8
Back
L.forearm Y Y Y Y Y Y Y Y
B.UL
L.RC BT 0 BB N
19 Sathish 14 Male Student Mid 2Yrsrs Hypo. P Patches 5 B.thighs Y Y Y Y Y Y Y
B.UL
BLP BT 0 BT N
20 Rajendran 44 Male Tailor Mid 6 mon
Hypo. P
Raised lesion
Patches
Nodules >20
Face
B.arms
Chest Back
B.thighs&
legs Y Y Y Y Y
Face Ear
lobe
Chest Y Y G & S
B.GA
B.UL
B.RC
S.N
B.LP
Ulcer
R.feet R.foot drop LL 6+ LL P
21 Subramanian 40 Male Labourer Low 3 mon
Hypo. P
Numbness Patches >20
Neck L.arm
Back chest
B.legs Y Y Y Y Y Ear lobe Y Y G & S
R.GA
B.UL
B.RC
B.LP LL 5+ LL P
22 Baskar 32 Male Labourer Low 1Yr Hypo. P Patches 8
Chest
L.knee
L.leg Y Y Y Y Y Y Y Y
B.UL
R.UL
B.LP BT 1+ BB N
23 Devi 55 Female
House
wife Low 4Yrs Hypo. P Patch 1 L.arm Y Y Y Y Y Y Y Y
B.UL
L.RC BT 0 BT N
24 Rajesh 24 Male Student Mid 2 mon
Raised lesions
Dry lesion Nodules Multiple
Chest back
Abdomen
B.arms
B.forearms Y Y Y Y Y Y Y
B.UL
B.RC
R.LP LL 4+ LL P
25 Sankar 39 Male Security Mid 1Yr Raised lesion Nodules Multiple
Chest
B.arms
B.forearms
Back
B.thighs &
legs Y Y Y Y Y Y Y G & S
R.UL
R.RC
R.LP LL 5+ LL P
26 Dilli 65 Male Coolie Low 8 mon Hypo. P
macules
Patches 16 Chest Back Y Y Y Y Y Y Y Y Y
B.UL
B.RC BB 3+ BL N
27 Venga sabapathy 31 Male Labourer Low 3Yrs Hypo. P Patches 3
L.elbow
R.arm Y Y Y Y Y Y Y Y
R.UL
R.RC BT 0 BT N
28 Padma 52 Female Coolie Low 4Yrs Hypo. P
macules
Patches >20
chest
BackB.arm
s
B.forearms
B.legs Y Y Y Y Y Y Y
B.UL
B.RC
R.LP
L.big toe
ulcer BL 5+ LL P
29 Navya 7 Female Student Mid 1Yr Raised lesion Plaque 1 R.cheek Y Y Y Y Y Y Y R.UL TT 0 TT N
30 Surendhar 16 Male Farmer Low 7Yrs Hypo. P  Patches 5 R.arm Back Y Y Y Y Y Y Y Y
R.UL
R.RC BT 0 BB N
31 Vishnu 14 Male Student Mid 4 mon Hypo. P Patches 2
R.forearm
R.leg Y Y Y Y Y Y Y
R.UL
R.LP TT 0 BT N
32 Fabuliah 19 Male Coolie Low 1Yr Hypo. P
macules
Patches >20
B.arms
B.forearms
chest Back
B.legs Y Y Y Y Y Y Y G & S
R.GA
B.UL
B.RC
B.LP BL 5+ LL P
33 Rajiv kumar nayak 28 Male Labourer Low 3 mon Hypo. P Patches 3 B.thighs Y Y Y Y Y Y Y Y
R.UL
R.LP BT 0 BT N
34 Mariyammal 47 Male
House
wife Low 2 mon
Hypo. P
swelling
Nodules
edema
Ulcer Multiple
B.hands
Face B.arm
L.feet Y Y Y Y Y
B.UL
B.RC
B.LP
R.SN
L.feet
ulcer BL 5+ BL P
35 Nagaraj 23 Male Mechanic Mid 3 mon Raised lesion Plaque 1 L.arm Y Y Y Y Y Y Y
R.UL
R.RC TT 0 TT N
36 Krishna moorthy 48 Male Labourer Low 1Yr Hypo. P
macules
Patches >20
Chest Back
Abdomen
B.arms &
forearms Y Y Y Y Y Y
B.UL
B.RC
B.LP BL 4+ BL P
37 Vikram 13 Male Student Mid 8 mon Hypo. P Patch 1 R.cheek Y Y Y Y Y Y Y
R.UL
R.RC TT 0 TT N
38 Chandrakanthan 65 Male No work Low 1 mon Raised lesion Plaques 15
Chest Back
B.arms Y Y Y Y Y Y Y
B.UL
B.RC
L.LP BB 3+ BT N
39 Selvam 22 Male Labourer Low 6 mon Raised lesion Nodules Multiple
B.arms
B.forearms
Chest Back
B.legs Y Y
Ear lobe
Face Y Y G & S
R.GA
B.UL
B.RC
B.LP LL 6+ LL P
40 Jaganathan 35 Male Coolie Low 6 mon Raised lesions Plaques 10
Mid face
Chest
B.forearms Y Y Y Y Y Y Y Y
B.UL
R.RC
R.LP BB 3+ BB N
41 Javid 22 Male Labourer Low 4 mon
Hypo. P
Numbness Patches >20
Chest Back
B.arms
B.forearms
B.thighs Y Y Y Y Y Ear lobe Y Y G & S
R.GA
B.UL
B.RC
R.LP R.claw hand LL 5+ LL P
42 Rama moorthy 32 Male Farmer Mid 1Yr Hypo. P Patches 3
B.arm &
forearms Y Y Y Y Y Y Y Y R.UL Y BT 0 BT N
43 Lakshmi 60 Female
House
wife Low 2Yrs Hypo. P Patches 2 R.forearm Y Y Y Y Y Y Y Y
R.UL
R.RC BT 0 BT N
44 Arunagiri 40 Male Coolie Low 6 mon Raised lesions Nodulels Multiple
Face Chest
Back
B.arms
B.forearms
B.Thighs Y Y
Face&
Ear lobe Y Y
B.UL
B.RC
R.LP
B.SN
Resorption of
toes LL 6+ LL P
45 Kavitha 18 Female Student Mid 8 mon Hypo. P Patch 1 L.forearm Y Y Y Y Y Y Y Y B.UL BT 0 BT N
46 Rama chandran 39 Male Farmer Mid 1Yr Hypo. P Patches 4
Chest
L.forearm Y Y Y Y Y Y Y Y
B.UL
L.RC BT 0 BT N
47 Kannan 45 Male Driver Mid 2Yrs Hypo .P
macules
Patches >20
B.arms
B.forearms
Chest Back
B.legs Y Y Y Y Y Y Y
B.GA
B.UL
B.RC
B.LP BL 4+ BL N
48 Thulasi 60 Female
House
wife Low 3Yrs
Raised lesions
Hypo. P
Macules
Nodules >20
Face
B.arms&
forearm
Chest Back
B.thighs Y Y Y Y Y
Ear
lobe&
over
macules Y Y G & S
R.GA
B.UL
B.RC
B.SN
R.LP
Ulcer
R.feet LL 5+ LL P
49 Ganesan 40 Male Coolie Low 9 mon Hypo. P
Macule
Patches >20
B.arm
Chest Back
B.thighs &
legs Y Y Y Y Y Y
B.UL
B.RC
B.LP BL 5+ BL P
50 Kamarasan 52 Male Coolie Low 3Yrs
Hypo. P
Raised lesion
Macules
Plaques >20
Face Chest
Back
B.arms
B.forearms
B.Thighs Y Y Y Y Y
Face&
Ear lobe Y Y G & S
B.GA
B.UL
B.RC
L.SN
B.LP
Resorption of
toes LL 6+ LL P
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